Vodafone and Exco InTouch partner to develop a Patient Reported Outcomes solution that will transform patient engagement in clinical trials

(26 June 2012) Vodafone, one of the world's largest mobile communications companies, announced today that it has signed an agreement with Exco InTouch, a leading provider of compliant, interactive mobile patient management solutions.

Together they will deliver Vodafone Patient Reported Outcomes (Vodafone PRO), a solution which has the potential to radically improve patient compliance and data quality in clinical research.

Vodafone PRO enables high quality data to be gathered as trial participants can report their experiences quickly and easily using their own mobile phone.  The service will be available on a global scale, benefiting from Vodafone’s international footprint and in-depth mobile and consumer insight, along with Exco InTouch’s extensive background in patient engagement. As more than 85% of the world’s population now own a mobile phone, the solution is using accessible technology that is firmly embedded in many people’s lives.

Exco InTouch’s solutions have been chosen by Vodafone as they provide simple, non-intrusive and compliant channels of communication. This enables sponsors and Contract Research Organisations to find and retain the right patients through engaging interactions and improved patient experience as well as offering customisable solutions to facilitate the collection of high quality patient data.

Axel Nemetz, Head of mHealth Solutions for Vodafone, said. “With this collaboration, Vodafone is confident that we can offer our clients the most innovative and effective clinical research solutions available in the global market. Our involvement will enable sponsors to choose our services for entire therapeutic areas around the world.” The initiative supports Vodafone’s strategy to expand its global and scalable healthcare services.

Tim Davis, CEO, Exco InTouch, comments: “Exco InTouch is delighted to enter into this complementary agreement with Vodafone. It demonstrates the extent to which mobile phone technology is increasingly being recognised by large pharmaceutical companies as an effective tool for the collection of clinical trial data. As a result of the partnership, research sponsors will be able to monitor safety and manage compliance in real time. This will make clinical trials easier and safer for patients, while enabling researchers to collect and process data quickly, accurately and reliably.”

Vodafone PRO can be configured for different study protocols in all phases of clinical research to collect crucial patient reported end point data. This scalable solution allows large volumes of high quality patient data to be securely transferred, validated and analysed in clinical trials. Vodafone PRO will make it easier for sponsors to retain and track people participating in trials and, through the patient-centred approach, is designed to improve the quality of data captured.

To learn more about this new partnership agreement, visit the Exco InTouch booth (#3201) at the DIA Annual Meeting, Philadelphia, 24-28 June, 2012.

For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.co.uk.

For further information on Vodafone mHealth Solutions, visit http://mhealth.vodafone.com.

-ENDS-

For further press information please contact: Michelle Valentine, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: exco@scottpr.com

About Exco InTouch

Exco InTouch is the trusted global innovator of regulatory compliant, mobile patient engagement solutions for life sciences and healthcare companies involved in clinical, late phase and mHealth research. Using a combination of patented software and services delivered in a cloud environment, Exco’s solutions can be utilised on any electronic device. This safe, secure platform facilitates compliant patient communication across the clinical development process from early phase development right through to long term studies and mHealth. As a result, Exco can help its customers to improve clinical outcomes by putting the patient at the heart of a study and enhancing the overall patient experience.

Exco’s solutions are currently being used by hundreds of thousands of patients in over seventy countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.

About Vodafone

Vodafone is one of the world's largest mobile communications companies by revenue with approximately 404 million customers in its controlled and jointly controlled markets as at 31 March 2012. Vodafone currently has equity interests in over 30 countries across five continents and more than 40 partner networks worldwide. For more information, please visit www.vodafone.com.

Exco InTouch is Named Microsoft Managed Partner within Life Sciences

Strengthened Partnership Facilitates Advancements in Patient Engagement Solutions

(25 June 2012) Exco InTouch, the leading provider of mobile patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, today announced that it has been named a Microsoft Managed Partner. Exco has been recognized by Microsoft’s Life Science team for the company’s unparalleled expertise in managing patients in regulatory and late phase clinical trials, as well as in the emerging mHealth space for marketed drugs.

Exco InTouch was selected based on a number of criteria, including the company’s established track record of providing unique solutions using cutting-edge technologies, in addition to revenue potential and growth. Exco InTouch is a global provider of regulatory compliant, simple and non-intrusive mobile patient communication solutions for clinical, late phase and mHealth studies. This enables sponsors and CROs to find and retain the right patients through engaging interactions and improved patient experience. The Managed Partner program will provide Exco InTouch with valuable resources to accelerate the adoption of its solutions in the life sciences market. 

Tim Davis of Exco InTouch said, “Exco InTouch is delighted to be included in the elite group of Microsoft Managed Partners. The early access we will receive to emerging Microsoft technologies, information, tools and support will enable us to develop the most advanced patient engagement solutions to date and our customers can look forward to experiencing these benefits as our partnership with Microsoft continues.”

“As the life sciences industry continues to adapt to increased regulatory standards and a higher volume of patients, new technology solutions have the potential to revolutionize the way we manage these processes, ” said Andrea McGonigle, managing director, Microsoft Life Sciences. “Exco InTouch is an example of a partner that can help companies deliver reliable data throughout their clinical and late phase studies in an accessible and user friendly way.”

For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.

-ENDS-

For further press information please contact: Michelle Valentine, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: exco@scottpr.com

About Exco InTouch

Exco InTouch is the trusted global innovator of regulatory compliant, mobile patient engagement solutions for life sciences and healthcare companies involved in clinical, late phase and mHealth research. Using a combination of patented software and services delivered in a cloud environment, Exco’s solutions can be utilised on any electronic device. This safe, secure platform facilitates compliant patient communication across the clinical development process from early phase development right through to long term studies and mHealth. As a result, Exco can help its customers to improve clinical outcomes by putting the patient at the heart of a study and enhancing the overall patient experience.

Exco’s solutions are currently being used by hundreds of thousands of patients in over seventy countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.

Exco InTouch Wins European Outsourcing Award for Second Year Running

Sawbridgeworth, UK – November 3, 2011- Exco InTouch, the leading provider of mobile patient communication solutions for the pharmaceutical and healthcare sectors, today announced another success in the prestigious European Outsourcing Awards, held in Frankfurt on 26 October 2011. In the second year running that the company has received the EOA award, Exco InTouch has been honoured with the accolade of ‘Best eBusiness/IT strategy’, which recognizes Exco InTouch’s collaboration with Pfizer. The study, which focused on new Research on Electronic Monitoring of OAB Treatment Experience (REMOTE), is the first Participatory Patient-Centred (PPC) clinical trial to be conducted. The Phase 4 trial was facilitated with the use of proven mobile eDiary technology from Exco InTouch, enabling patients to participate regardless of location, age or proximity to site.

In order to support the success of this patient-centred, field-based study, Pfizer required a mobile technology platform offering an ease-of-use interface that provided accessibility, particularly with older patients in mind. The familiar, light-weight and accessible nature of a regular cell phone loaded with intuitive software meant it was the natural choice for Pfizer. These ePRO diaries enabled Pfizer to interact directly with study participants in a personalised and cost-effective manner, sending reminders and motivational messages directly to the patient’s cell phone. As a result, this improved patient compliance and retention, increasing overall data accuracy. Patients were also able to manage their own trial remotely and report results directly to a trial investigator who kept close oversight of patient eligibility and safety.

Since its inception in 2005, the EOA awards has recognised new and significant developments in contract services and rewarded successful companies for their outstanding contribution to the industry throughout the year. Despite strong competition from multiple industry competitors, the EOA crowned Exco InTouch winners of the award for their contribution in facilitating the revolutionary study with its innovative eDiary technology and flexible, customised service. EOA judges were impressed by the potential of the cellphone-based ePRO technology to transform how patients access and participate in clinical trials and to accelerate clinical research while improving quality.
Tim Davis, CEO of Exco InTouch comments, “It is a great honour to win an award that recognizes the collaboration between Exco InTouch and Pfizer and the integral part Exco’s leading ePRO technology played in the revolutionary study. Together we have been able to meet our joint objective to focus on innovative advancements that will accelerate clinical research through enhanced data quality and improvement in the way that patients all over the world can access clinical trials.”

For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.


About Exco InTouch
Exco InTouch is the leading provider of regulatory compliant interactive mobile patient communication solutions for Patient Recruitment, Retention, Compliance, ePRO/eDiary and Late Phase studies. Using a combination of software and services, Exco InTouch solutions provide simple, quick and non-intrusive channels of communication that enables sponsors, CROs, sites and patient recruitment agencies, find the right patients; keep them in their studies; motivate them to maintain full compliance and facilitate the collection of quality patient data, thus ensuring a better overall patient experience.

These solutions are currently being used by hundreds of thousands of patients in over 70 countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.

For more info on Exco InTouch visit http://www.excointouch.com

Exco InTouch Wins Deloitte Technology Fast 50 Award in Recognition of Significant Growth

(Sawbridgeworth, UK, October 24 2011) Exco InTouch, the leading provider of patient communication solutions for the pharmaceutical and healthcare sectors, today announced that it is a winner of the 2011 Deloitte Technology Fast 50. The awards, now in their 14th year, are an independent ranking of the 50 fastest growing technology companies in the UK, based on percentage growth in revenue over five years. Exco InTouch was placed as the 44th fastest growing company in the country and the 7th fastest growing company in the South East region. Receipt of the Fast 50 award is a significant achievement, recognising growth based on innovation and entrepreneurship. Exco InTouch’s win comes on the back of a recent growth investment from leading growth equity and venture capital group Scottish Equity Partners (SEP).

Exco InTouch, whose clients include nine of the world’s top 10 pharmaceutical businesses, offers an innovative suite of patient-focused services which are delivered using a combination of cell-phone and internet technology. Used in clinical trials, the company’s services benefit both patients and pharmaceutical clients, providing patient recruitment and retention support. These unique services result in improved overall compliance and the facilitation of the electronic capture of patient reported outcomes data (ePRO) during clinical trials and in Late Phase observational studies. The business, which employs some 40 staff, has its headquarters in the UK and offices in the United States and recently opened a second UK office in Nottingham to accommodate up to 30 more staff.

With the recent £3m investment from SEP, Exco InTouch is entering its next growth phase, enabling it to invest further in people, technology and infrastructure and to further enhance its revolutionary mobile technology platform. SEP has taken a minority stake in the company. Exco InTouch will use the funds to take advantage of significant growth opportunities in the clinical trial sector, particularly in the emerging mobile patient communication market. Demand for its services is growing exponentially as pharmaceutical companies are increasingly adopting smart technology to optimise clinical trial execution.

“Making the Deloitte Technology Fast 50 is a testament to a company’s commitment to technology”, says Mark Doleman, Regional Partner, Deloitte UK Technology Fast 50 and Technology Fast 500 EMEA Programmes. “With its 730% growth rate over five years, Exco InTouch has proven that its leadership has the vision and determination to grow in competitive conditions.”

“The Deloitte UK Technology Fast 50 is internationally recognised as being one of the most important business awards in the sector and we are thrilled to receive this accreditation”, comments Tim Davis, CEO of Exco InTouch. “Despite economic uncertainty, the past five years have proved highly successful for us, with particular growth in our ePRO and patient engagement services. We look forward to this continued growth in the future as sponsors increasingly recognise the benefits of our mobile technology in the healthcare and drug development sectors.”


For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.

For further press information please contact: Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: exco@scottpr.com

About Exco InTouch:
Exco InTouch is the leading provider of regulatory compliant interactive mobile patient communication solutions for Patient Recruitment, Retention, Compliance, ePRO/eDiary and Late Phase studies. Using a combination of software and services, Exco InTouch solutions provide simple, quick and non-intrusive channels of communication that enables sponsors, CROs, sites and patient recruitment agencies, find the right patients; keep them in their studies; motivate them to maintain full compliance and facilitate the collection of quality patient data, thus ensuring a better overall patient experience.
These solutions are currently being used by hundreds of thousands of patients in over 70 countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.


About Deloitte:
In this press release references to Deloitte are references to Deloitte LLP, which is among the country's leading professional services firms.

Deloitte LLP is the United Kingdom member firm of Deloitte Touche Tohmatsu (‘DTT’), a Swiss Verein, whose member firms are legally separate and independent entities. Please see www.deloitte.co.uk/about for a detailed description of the legal structure of DTT and its member firms.

The information contained in this press release is correct at the time of going to press.

For more information, please visit www.deloitte.co.uk.

Deloitte Technology, Media & Telecommunications (TMT) Group
The Deloitte TMT Group is composed of service professionals who have a wealth of experience serving technology, media and telecommunications companies throughout the UK in areas including cable, communications providers, computers and peripherals, entertainment, media and publishing, networking, semiconductors, software, wireless, and related industries. These specialists understand the challenges that these companies face throughout all stages of their business growth cycle and are committed to helping them succeed. Deloitte is a leader in providing strategic, financial and operational assistance to its technology, media and telecommunications clients.

For more information, please visit www.deloitte.co.uk/tmt

EXCO INTOUCH SECURES GROWTH INVESTMENT FROM SEP

Mobile patient communication leader to use funds to accelerate growth strategy

LONDON, UK - 29 September, 2011 - Leading growth equity and venture capital group Scottish Equity Partners (SEP) has led an initial £3m pound investment in Exco InTouch, the leading provider of mobile patient communication and management solutions for the pharmaceutical and healthcare sector.

SEP has taken a minority stake in the company which will use the funds to accelerate its expansion, enabling it to take advantage of significant growth opportunities in the clinical technology sector, particularly in the emerging mobile patient communication market.

Pfizer Selects Exco InTouch’s Novel eDiary Technologies to Initiate First Ever Patient-Centered Clinical Trial

(20 June, 2011) Exco InTouch, the leading provider of patient communication solutions for the pharmaceutical and healthcare sectors, has announced that its novel eDiary technologies have been selected by Pfizer, the world’s leading pharmaceutical company, as part of the first ever Participatory Patient-Centered (PPC) clinical trial. The pilot study will utilize Exco InTouch’s leading eDiary technologies to enable patients to participate regardless of location, age or proximity to site.  Focusing on new Research on Electronic Monitoring of OAB Treatment Experience (REMOTE) Phase 4 for the treatment of overactive bladder, the study will mimic a previously completed trial in order to replicate the results and validate this novel approach.

In order to support the success of this patient-centered, field-based clinical research, Pfizer required a mobile technology platform offering an ease-of-use interface that provided accessibility particularly for older patients.  With an estimated five billion cellphone users worldwide, cell phones make an ideal and accessible platform for patient engagement in clinical trials. As part of the revolutionary new approach piloted by the REMOTE study, patients will be empowered to participate remotely in the screening process through trials via the internet, participate in trials that due to location may not have previously been possible, actively manage their own trial and report results directly to a trial. As a result, researchers expect to save time and obtain more reliable, higher quality data through increased patient compliance and engagement, lower withdrawal rates and real-time data collection. The new approach will also eliminate the significant costs associated with the management and co-ordination of running multiple clinical sites.